

May 30, 2016

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir,

Sub: Audited Financial Results for the year ended 31st March 2016.

The Board of Directors of the Company at the meeting held on 30th May 2016 has inter-alia considered and approved the Audited Financial Results of the Company for the year ended 31st March 2016. Pursuant to regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we enclose herewith the Audited Financial Results of the Company along with the Auditors Report issued by the Statutory Auditors and Declaration with regard to Auditor's Report with unmodified opinion.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED



A.MOHAN RAMI REDDY
Vice President (Legal) & Company Secretary



AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059
Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurobindo.com (Rs. In lakhs)

STATEMENT OF STANDALONE AUDITED RESULTS FOR THE YEAR ENDED 31.03.2016

Particulars	Standalone				
	Three months ended			Year Ended	
	31.03.2016	31.12.2015	31.03.2015	31.03.2016	31.03.2015
	Audited (Refer note 9)	Unaudited	Audited (Refer note 9)	Audited	Audited
1 Income from operations					
(a) Net sales/income from operations (Net of excise duty)	233,425	230,202	202,042	892,238	801,800
(b) Other operating income	7,160	6,276	1,799	24,380	7,710
Total income from operations (net)	240,585	236,478	203,841	916,618	809,510
2 Expenses					
(a) Cost of material consumed	112,399	114,986	104,033	442,580	392,033
(b) Purchase of stock-in-trade	155	273	114	631	1,576
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	146	(7,462)	(10,382)	(14,159)	(15,909)
(d) Employee benefits expense	21,423	20,689	18,851	80,980	66,875
(e) Depreciation and amortisation expense	6,711	6,721	6,266	26,300	24,515
(f) Provision for decline in the value of long-term investment	4,550	-	5,400	4,550	5,400
(g) Other expenses	41,044	38,946	35,779	157,133	134,493
Total expenses	186,428	174,153	160,061	698,015	608,983
3 Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)	54,157	62,325	43,780	218,603	200,527
4 Other Income	984	171	627	3,929	4,232
5 Profit/(Loss) from ordinary activities before finance costs , foreign exchange (gain)/ loss and exceptional items (3+4)	55,141	62,496	44,407	222,532	204,759
6 Finance costs (refer note 4)	1,616	1,740	1,409	6,527	5,658
7 Foreign exchange (Gain)/Loss (refer note 4)	(415)	(551)	212	2,000	5,067
8 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)	53,940	61,307	42,786	214,005	194,034
9 Exceptional item					
10 Profit /(Loss) from ordinary activities before tax (8-9)	53,940	61,307	42,786	214,005	194,034
11 Tax expense/(credit)	13,155	14,736	9,085	52,038	42,400
12 Net Profit /(Loss) for the period (10-11)	40,785	46,571	33,701	161,967	151,634
13 Paid-up Equity Share Capital (Face value Re. 1 per share)	5,852	5,840	2,920	5,852	2,920
14 Reserves excluding Revaluation Reserve				675,200	533,034
15 Earnings per share of Re.1/- each (not annualised)					
(a) Basic	6.97	7.97	5.77	27.73	26.00
(a) Diluted	6.97	7.97	5.77	27.72	25.98

NOTES:

- The above standalone audited financial results as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on May 30, 2016.
- The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- FOB value of exports for standalone is Rs.709,268 Lakhs for the current year (March 31, 2015 Rs.625,141 lakhs).
- Foreign exchange (gain)/loss for stand alone results includes exchange difference of Rs.520 lakhs , Rs.2,064 lakhs, Rs.Nil, for three months ended March 31, 2016, December 31, 2015, and March 31, 2015 respectively and Rs.16,404 lakhs, Rs. 7,556 lakhs for the year ended March 31, 2016 and March 31, 2015 respectively arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of "AS 16" on Borrowing costs.
- The Board of Directors at their meeting held on September 12, 2013 decided to transfer its injectable unit of the Company on a going concern basis comprising assets and liabilities pertaining to the said unit to its wholly owned subsidiary Curepro Parenterals Limited w.e.f. April 1, 2014. The same is subject to requisite consent, approval or permission of the statutory or regulatory authorities. Pending such approvals, no effect of this scheme has been given in the above results.
- The Company on July 22, 2015, had allotted 291,982,275 equity shares of Re.1/- each to the shareholders of the Company as Bonus shares in the ratio of 1:1. Consequent to the aforesaid allotment, the paid up equity share capital of the Company had increased from 291,982,275 Equity Shares of Re.1/- each to 583,964,550 Equity Shares of Re.1/- each. The earnings per share has been adjusted for bonus issue for previous periods presented in accordance with Accounting Standard 20, Earning per share.
- The Company has allotted 855,000 equity shares of Re.1/- each on January 19, 2016 and 350,036 equity shares of Re.1/- each on March 09, 2016 to the employees under Employee Stock Option Plan 2006. Consequent to the allotment the paid up share capital of the Company has increased to 585,169,586 equity shares of Re.1/- each.
- During the quarter (i) Actavis France SAS, a step down subsidiary has been merged with Arrow Generiques SAS, France, another step down subsidiary retrospectively from 1st April, 2015. (ii) Milpharm Limited, a stepdown subsidiary was acquired by Agile Pharma B.V., another step down subsidiary from Helix Healthcare B.V., a Subsidiary of the Company. (iii) Aurobindo Pharma (Singapore) Pte Limited, a stepdown subsidiary, was liquidated w.e.f December 31, 2015.
- The figures of last quarter are the balancing figures between audited figures in respect of the full financial year ended March 31st and unaudited published year to date figures upto December 31st being the date of the end of the third quarter of the financial year which were subjected to a limited review.
- The Board has approved fourth interim dividend @70% i.e. Rs.0.70 per equity share of Rs.1/- for the year 2015-16. This is in addition to interim dividend @ 50%, 60% and 70% on equity share capital of Company i.e. Rs. 0.50, Rs. 0.60 and Rs.0.70 per share paid in September, 2015, November, 2015 and March, 2016 respectively for the year 2015-16. The Board of Directors does not recommend any further dividend for the year 2015-16.
- We declare that the Audit Report on the above financial results are with unmodified opinion.
- Previous period / year figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.

Place: Hyderabad
Date: May 30, 2016



www.aurobindo.com



By Order of the Board

N. Govindarajan
Managing Director

Rs. In lakhs

Statement of Assets and Liabilities

Particulars	Standalone	
	As At 31.03.2016	As At 31.03.2015
	Audited	Audited
A EQUITY AND LIABILITIES		
1 Shareholders' funds		
(a) Share capital	5,852	2,920
(b) Reserves and surplus	675,200	533,034
Sub-total - Shareholders' funds	681,052	535,954
2 Non-current liabilities		
(a) Long-term borrowings	33,476	68,716
(b) Deferred tax liabilities (net)	21,249	21,034
(c) Long-term provisions	2,126	2,265
Sub-total - Non-current liabilities	56,851	92,015
3 Current liabilities		
(a) Short-term borrowings	257,457	220,937
(b) Trade payables	128,213	114,604
(c) Other current liabilities	59,092	50,476
(d) Short-term provisions	10,625	8,602
Sub-total - Current liabilities	455,387	394,619
TOTAL- EQUITY AND LIABILITIES	1,193,290	1,022,588
B ASSETS		
1 Non-current assets		
(a) Fixed assets	331,026	241,720
(b) Non-current investments	118,236	99,311
(c) Long-term loans and advances	41,731	41,894
(d) Other non-current assets	2,723	2,855
Sub-total - Non-current assets	493,716	385,780
2 Current assets		
(a) Current investments	2	1,964
(b) Inventories	243,160	214,505
(c) Trade receivables	354,114	370,894
(d) Cash and cash equivalents	33,081	1,113
(e) Short-term loans and advances	46,812	40,085
(f) Other current assets	22,405	8,247
Sub-total - Current assets	699,574	636,808
TOTAL - ASSETS	1,193,290	1,022,588



28



Auditor's Report On Quarterly Unconsolidated Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
Board of Directors of
Aurobindo Pharma Limited,

1. We have audited the quarterly unconsolidated financial results of Aurobindo Pharma Limited ('the Company') for the quarter ended March 31, 2016 and the unconsolidated financial results for the year ended March 31, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The quarterly unconsolidated financial results are the derived figures between the audited figures in respect of the year ended March 31, 2016 and the published year-to-date figures up to December 31, 2015, being the date of the end of the third quarter of the current financial year, which were subject to limited review. The unconsolidated financial results for the quarter ended March 31, 2016 and year to date ended March 31, 2016 have been prepared on the basis of the unconsolidated financial results for the nine-month period ended December 31, 2015, the audited annual unconsolidated financial statements as at and for the year ended March 31, 2016, and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these unconsolidated financial results based on our review of the unconsolidated financial results for the nine-month period ended December 31, 2015 which was prepared in accordance with the recognition and measurement principles laid down in Accounting Standard (AS) 25, Interim Financial Reporting, specified under the Section 133 of the Companies Act 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India; our audit of the annual unconsolidated financial statements as at and for the year ended March 31, 2016; and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. In our opinion and to the best of our information and according to the explanations given to us these quarterly unconsolidated financial results as well as the year to date results:
 - i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and
 - ii. give a true and fair view of the net profit and other financial information for the quarter ended March 31, 2016 and for the year ended March 31, 2016.



S.R. BATLIBOI & ASSOCIATES LLP


Chartered Accountants

4. Further, read with paragraph 1 above, we report that the figures for the quarter ended March 31, 2016 represent the derived figures between the audited figures in respect of the financial year ended March 31, 2016 and the published year-to-date figures up to December 31, 2015, being the date of the end of the third quarter of the current financial year, which were subjected to a limited review as stated in paragraph 1 above, as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm Registration Number: 101049W/E300004



per Vikas Kumar Pansari

Partner

Membership Number.: 093649



Place: Hyderabad

Date: May 30, 2016

AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurobindo.com (Rs. In lakhs)

STATEMENT OF CONSOLIDATED AUDITED RESULTS FOR THE YEAR ENDED 31.03.2016

Particulars	Consolidated				
	Three months ended			Year Ended	
	31.03.2016	31.12.2015	31.03.2015	31.03.2016	31.03.2015
	Unaudited	Unaudited	Unaudited	Audited	Audited
1 Income from operations					
(a) Net sales/income from operations (Net of excise duty)	367,470	343,208	314,397	1,365,061	1,204,323
(b) Other operating income	7,205	6,342	1,810	24,547	7,729
Total income from operations (net)	374,675	349,550	316,207	1,389,608	1,212,052
2 Expenses					
(a) Cost of material consumed	123,241	123,897	103,234	482,489	412,281
(b) Purchase of stock-in-trade	39,294	37,748	33,657	143,213	171,227
(c) Changes in inventories of finished goods, work-in- progress and stock-in-trade	178	(6,290)	469	(9,949)	(32,948)
(d) Employee benefits expense	40,882	40,102	37,332	155,084	130,226
(e) Depreciation and amortisation expense	11,127	9,947	8,467	39,262	33,261
(f) Other expenses	82,847	71,792	75,906	298,213	274,904
Total expenses	297,569	277,196	259,065	1,108,312	988,951
3 Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)	77,106	72,354	57,142	281,296	223,101
4 Other Income	2,059	687	674	6,823	8,076
5 Profit/(Loss) from ordinary activities before finance costs , foreign exchange (gain)/ loss and exceptional items (3+4)	79,165	73,041	57,816	288,119	231,177
6 Finance costs (refer note 4)	2,511	2,270	2,260	9,273	8,431
7 Foreign exchange (Gain)/Loss (refer note 4)	(455)	(1,293)	(119)	6,600	5,960
8 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)	77,109	72,064	55,675	272,246	216,786
9 Exceptional item					
10 Profit /(Loss) from ordinary activities before tax (8-9)	77,109	72,064	55,675	272,246	216,786
11 Tax expense/(credit)	20,965	18,599	15,340	74,437	59,660
12 Net Profit /(Loss) for the period (10-11)	56,144	53,465	40,335	197,809	157,126
13 Minority Interest	(141)	(30)	(45)	(391)	(451)
14 Net Profit/(Loss) after taxes and minority interest (12-13)	56,285	53,495	40,380	198,200	157,577
15 Paid-up Equity Share Capital (Face value Re. 1 per share)	5,852	5,840	2,920	5,852	2,920
16 Reserves excluding Revaluation Reserve				699,821	512,670
17 Earnings per share of Re.1/- each (not annualised)					
(a) Basic	9.64	9.16	6.92	33.93	27.03
(a) Diluted	9.63	9.16	6.91	33.92	27.00

- NOTES:**
- The above consolidated audited financial results as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on May 30, 2016.
 - The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement' and AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all Subsidiaries and a Joint Venture.
 - The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
 - Foreign exchange (gain)/loss for consolidated results includes exchange difference of Rs.520 lakhs , Rs.2,064 lakhs, Rs.Nil, for three months ended March 31, 2016, December 31, 2015, and March 31, 2015 respectively and Rs.16,404 lakhs, Rs. 7,556 lakhs for the year ended March 31, 2016 and March 31, 2015 respectively arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of "AS 16" on Borrowing costs.
 - The Board of Directors at their meeting held on September 12, 2013 decided to transfer its injectable unit of the Company on a going concern basis comprising assets and liabilities pertaining to the said unit to its wholly owned subsidiary Curepro Parenterals Limited w.e.f. April 1, 2014. The same is subject to requisite consent, approval or permission of the statutory or regulatory authorities. Pending such approvals, no effect of this scheme has been given in the above results.
 - During the previous year, on December 4, 2014, Company's USA subsidiary Aurobindo Pharma USA Inc. has acquired Natrol LLC, USA, The above Consolidated results for the quarter and year ended March 31, 2016 and for the year ended March 31, 2015 includes financial results of operations of Natrol LLC, USA from December 4, 2014. The corresponding figures of the year ended March 31, 2016 are not comparable.
 - The Company on July 22, 2015, had allotted 291,982,275 equity shares of Re.1/- each to the shareholders of the Company as Bonus shares in the ratio of 1:1. Consequent to the aforesaid allotment, the paid up equity share capital of the Company had increased from 291,982,275 Equity Shares of Re.1/- each to 583,964,550 Equity Shares of Re.1/- each. The earnings per share has been adjusted for bonus issue for previous periods presented in accordance with Accounting Standard 20, Earning per share.
 - The Company has allotted 855,000 equity shares of Re.1/- each on January 19, 2016 and 350,036 equity shares of Re.1/- each on March 09, 2016 to the employees under Employee Stock Option Plan 2006. Consequent to the allotment the paid up share capital of the Company has increased to 585,169,586 equity shares of Re.1/- each.
 - During the quarter (i) Actavis France SAS, a step down subsidiary has been merged with Arrow Generiques SAS, France, another step down subsidiary retrospectively from 1st April, 2015. (ii) Milpharm Limited, a stepdown subsidiary was acquired by Agile Pharma B.V., another step down subsidiary from Helix Healthcare B.V., a Subsidiary of the Company. (iii) Aurobindo Pharma (Singapore) Pte Limited a stepdown subsidiary was liquidated w.e.f December 31, 2015.
 - The figures of the quarter ended March 31, 2016, March 31, 2015 and December 31, 2015 are not subject to an audit/limited review.
 - We declare that the Audit Report on the above financial results are with unmodified opinion.
 - The Board has approved fourth interim dividend @70% i.e. Rs.0.70 per equity share of Rs.1/- for the year 2015-16. This is in addition to interim dividend @ 50%, 60% and 70% on equity share capital of Company i.e. Rs. 0.50, Rs. 0.60 and Rs.0.70 per share paid in September, 2015, November, 2015 and March, 2016 respectively for the year 2015-16. The Board of Directors does not recommend any further dividend for the year 2015-16.
 - Previous period / year figures have been rounded/rearranged wherever considered necessary to conform to the current period presentation.

Place: Hyderabad
Date :May 30 , 2016



www.aurobindo.com



By Order of the Board
N. Govindarajan
Managing Director

Rs. In lakhs

Statement of Assets and Liabilities

	Particulars	Consolidated	
		As At 31.03.2016	As At 31.03.2015
		Audited	Audited
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	5,852	2,920
	(b) Reserves and surplus	699,821	512,670
	Sub-total - Shareholders' funds	705,673	515,590
2	Minority interest	5,955	2,582
3	Non-current liabilities		
	(a) Long-term borrowings	84,720	136,147
	(b) Deferred tax liabilities (net)	23,645	21,054
	(c) Long-term provisions	2,354	2,435
	Sub-total - Non-current liabilities	110,719	159,636
4	Current liabilities		
	(a) Short-term borrowings	322,902	250,208
	(b) Trade payables	252,677	205,112
	(c) Other current liabilities	153,737	136,496
	(d) Short-term provisions	18,272	21,824
	Sub-total - Current liabilities	747,588	613,640
	TOTAL - EQUITY AND LIABILITIES	1,569,935	1,291,448
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	517,485	406,126
	(b) Goodwill on consolidation	8,869	6,401
	(c) Non-current investments	14	14
	(d) Deferred tax assets (net)	9	475
	(e) Long-term loans and advances	40,101	45,527
	(f) Other non-current assets	3,310	3,025
	Sub-total - Non-current assets	569,788	461,568
2	Current assets		
	(a) Current investments	2	1,965
	(b) Inventories	408,810	361,130
	(c) Trade receivables	417,192	353,917
	(d) Cash and cash equivalents	83,439	46,911
	(e) Short-term loans and advances	64,538	56,842
	(f) Other current assets	26,166	9,115
	Sub-total - Current assets	1,000,147	829,880
	TOTAL - ASSETS	1,569,935	1,291,448



28



Auditor's Report On Consolidated Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To
**Board of Directors of
Aurobindo Pharma Limited,**

1. We have audited the consolidated financial results of Aurobindo Pharma Limited ('the Company'), comprising its subsidiaries (together, 'the Group'), and a joint venture, for the year ended March 31, 2016, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The consolidated financial results for the year ended March 31, 2016 have been prepared on the basis of the audited annual consolidated financial statements as at and for the year ended March 31, 2016 and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and are the responsibility of the Company's management and have been approved by the Board of Directors of the Company. Our responsibility is to express an opinion on these consolidated financial results based on our audit of the annual consolidated financial statements as at and for the year ended March 31, 2016 which were prepared in accordance with the applicable accounting standards and other accounting principles generally accepted in India and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
2. We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatements. An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
3. We did not audit the total assets of Rs. 764,800 lakhs as at March 31, 2016 and total revenues of Rs. 859,497 lakhs for the year then ended, included in the accompanying consolidated financial statements in respect of 52 subsidiaries, and a joint venture, whose financial statements and other financial information have been audited by other auditors and whose reports have been furnished to us. Our opinion, in so far as it relates to the affairs of such subsidiaries and joint venture is based solely on the report of other auditors. Our opinion is not qualified in respect of this matter.
4. In our opinion and to the best of our information and according to the explanations given to us, these consolidated financial results for the year:
 - a. include the year-to-date results of the following entities;
 - i. APL Pharma Thai Limited
 - ii. All Pharma (Shanghai) Trading Co Limited
 - iii. Aurobindo Pharma USA Inc
 - iv. Aurobindo Pharma Industria Farmaceutica Ltda
 - v. Helix Healthcare BV
 - vi. APL Holdings (Jersey) Limited (upto November 18, 2015)



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

- vii. Aurobindo Pharma Produtos Farmaceuticos Ltda
- viii. APL Healthcare Limited
- ix. Auronext Pharma Private Limited
- x. APL Research Centre Limited
- xi. Auro Pharma Inc
- xii. Aurobindo Pharma (Pty) Limited
- xiii. Aurobindo Pharma (Australia) Pty Ltd (upto April 10, 2015)
- xiv. Agile Pharma BV
- xv. Auro Healthcare (Nigeria) Limited
- xvi. Aurobindo ILAC Sanayi ve Ticaret Limited Sirketi
- xvii. Aurobindo Pharma (Singapore) Pte Limited (upto December 31, 2015)
- xviii. Aurobindo Pharma Japan KK
- xix. Aurex BV (formerly known as Pharmacin BV)
- xx. Aurobindo Pharma GmbH
- xxi. Aurobindo Pharma (Portugal) Unipessoal LDA
- xxii. Actavis France SAS (Merged with Arrow Generiques SAS)
- xxiii. Laboratorios Aurobindo SL
- xxiv. Aurobindo Pharma BV (Upto June 30, 2015)
- xxv. Aurobindo Pharma (Romania) srl
- xxvi. Aurobindo Pharma (Italia) Srl
- xxvii. Aurobindo Pharma (Malta) Limited
- xxviii. APL IP Company Limited, Jersey
- xxix. APL Swift Services (Malta) Limited
- xxx. Milpharm Limited
- xxxi. Aurolife Pharma LLC
- xxxii. Auro Peptides Limited
- xxxiii. Auromedics Pharma LLC
- xxxiv. Aurobindo Pharma NZ Limited (upto April 10, 2015)
- xxxv. Aurovida Farmaceutica SA de CV
- xxxvi. Curepro parenterals Limited
- xxxvii. Hyacinths Pharma Private Limited
- xxxviii. Silicon Life Sciences Private Limited
- xxxix. AuroZymes Limited
 - xl. Eugia Pharma Specialities Limited
 - xli. Aurobindo Pharma Colombia SAS
 - xl.ii. Aurovitas, Unipessoal LDA
 - xl.iii. Arrow Generiques SAS
 - xl. iv. Aurobindo Pharma BV (formerly known as Actavis BV)
 - xl. v. Auro Health LLC
 - xl. vi. Aurobindo Antibiotics Limited
 - xl. vii. Pharmacin BV (formerly known as Aurex BV)
 - xl. viii. 1980 Puren Pharma GmbH (formerly known as Actavis Management GmbH)
 - xl. ix. Puren Pharma GmbH & Co, KG (formerly known as Actavis Deutschland GmbH & Co, KG)
 - l. Aurovitas Spain SA (formerly known as Actavis Spain SA)
 - li. Natrol LLC
 - lii. Novagen Pharma (Pty) Limited
 - liii. Tergene Biotech Private Limited (from April 01, 2015)



S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

- b. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in this regard; and
- c. give a true and fair view of the consolidated net profit and other financial information for the consolidated year to date results for the year ended March 31, 2016.

For S.R. BATLIBOI & ASSOCIATES LLP

ICAI Firm Registration Number: 101049W/E300004

Chartered Accountants



per Vikas Kumar Pansari
Partner

Membership Number: 93649



Place: Hyderabad

Date: May 30, 2016

DECLARATION

Pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

We hereby declare and confirm that Auditor's Report on Annual Financials of the Company for the year ended 31st March 2016 is with unmodified opinion.

This declaration is furnished pursuant to Regulation 33(3)(d) of the SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016 vide Notification NRO / GN / 2016-17 / 001 dated 25.05.2016.

For AUROBINDO PHARMA LIMITED


N.GOVINDARAJAN
Managing Director



AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059
Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com